Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Gastrointestinal Stromal Tumors 31Sarcoma 7Osteosarcoma 4Sarcoma, Alveolar Soft Part 3Neoplasm Metastasis 3Leiomyosarcoma 3Histiocytoma, Malignant Fibrous 3Gliosarcoma 3Gastrointestinal Neoplasms 3Carcinoma, Renal Cell 3Sarcoma, Synovial 2Liposarcoma 2Hemangiosarcoma 2Glioma 2Glioblastoma 2Fibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Chondrosarcoma 2Carcinoma, Non-Small-Cell Lung 2Bone Neoplasms 2Adenoma, Islet Cell 2Thyroid Neoplasms 1Somatostatinoma 1Solitary Fibrous Tumors 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Ovarian Neoplasms 1

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Nivolumab 1Laparoscopy 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Sunitinib × Sarcoma × Clear all
NCT00478426 2020-02-17

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
34 enrolled 10 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡